RHB-102 (BEKINDA®) (24 mg) is an investigational drug in development in the UK for the management of chemotherapy and radiotherapy induced nausea and vomiting, otherwise known as CINV and RINV in adults.
RHB-102 is a once-daily, bimodal extended-release, oral tablet formulation of the antiemetic drug ondansetron, a 5-HT3 antagonist, and is intended to provide patients with relief from nausea and vomiting symptoms for a 24-hour period with a single oral tablet.
On February 25, 2025, we entered into an exclusive worldwide development and commercialization licensing agreement, excluding North America, with Hyloris Pharmaceuticals for RHB-102 for gastroenteritis & gastritis, IBS-D and oncology support. Learn more.